# **Supporting Information**

#### **Table of Contents**

Figure S1. <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of <b>5</b> .	2
Figure S2. $^{13}$ C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of 5.	3
Figure S3. <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of 6.	4
Figure S4. <sup>13</sup> C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of $6$ .	5
Figure S5. HSQC (150 MHz, CDCl <sub>3</sub> ) spectrum of 6.	6
Table S1. NMR assignments 7a/7b mixture.	7
Figure S6. <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of <b>7a/7b</b> mixture.	8
Figure S7. <sup>13</sup> C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of 7a/7b mixture.	9
Figure S8. HSQC spectrum (600 MHz, CDCl <sub>3</sub> ) of 7a/7b mixture.	10
Figure S9. MS (top) and MSMS spectra (bottom) of 7a/7b.	11
Figure S10. Analytical UPLC Chromatogram of 7a/7b. (a) UV trace 255 nm; (b) ELSD trace; (c)	Base
peak mass chromatogram; (d) Selected ion monitoring $m/z$ 390 [M + H]; (e) Average mass	
spectrum (5.15–5.45 min).	12
<b>Figure S11.</b> <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of <b>8</b> .	13
Figure S12. <sup>13</sup> C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of $8$ .	14
<b>Figure S13.</b> <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of <b>10</b> .	15
Figure S14. $^{13}$ C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of 10.	16
<b>Figure S15.</b> <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of <b>11</b> .	17
Figure S16. $^{13}$ C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of 11.	18
<b>Figure S17.</b> <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of <b>12</b> .	19
Figure S18. $^{13}$ C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of 12.	20
<b>Figure S19.</b> <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of <b>14</b> .	21
Figure S20. $^{13}$ C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of 14.	22
<b>Figure S21.</b> <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of <b>15</b> .	23
Figure S22. $^{13}$ C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of 15.	24
<b>Figure S23.</b> <sup>1</sup> H-NMR (600 MHz, CDCl <sub>3</sub> ) spectrum of 16.	25
Figure S24. $^{13}$ C-NMR (150 MHz, CDCl <sub>3</sub> ) spectrum of 16.	26
Figure S25. <sup>1</sup> H-NMR (600 MHz, $C_6D_6$ ) spectrum of 17.	27
<b>Figure S26.</b> ${}^{13}$ C-NMR (600 MHz, C <sub>6</sub> D <sub>6</sub> ) spectrum of <b>17</b> .	28
<b>Figure S27.</b> <sup>1</sup> H-NMR (600 MHz, $(CD_3)_2SO$ ) spectrum of <b>18</b> .	29
<b>Figure S28.</b> <sup>13</sup> C-NMR (600 MHz, (CD <sub>3</sub> ) <sub>2</sub> SO) spectrum of <b>18</b> .	30
<b>Figure S29.</b> <sup>1</sup> H-NMR (600 MHz, $CD_3OD$ ) spectrum of <b>19</b> .	31
<b>Figure S30.</b> <sup>13</sup> C-NMR (600 MHz, CD <sub>3</sub> OD) spectrum of <b>19</b> .	32
<b>Figure S31.</b> <sup>1</sup> H-NMR (600 MHz, $(CD_3)_2SO$ ) spectrum of <b>20</b> .	33
Figure S32. <sup>13</sup> C-NMR (600 MHz, (CD <sub>3</sub> ) <sub>2</sub> SO) spectrum of 20.	34
<b>Scheme S1.</b> Syntheses of 2,3,4,6-tetra- <i>O</i> -benzoyl-β-d-galactopyranosyl trichloroacetimidate ( <b>21</b> ).	35



**Figure S1.** <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of **5**.



Figure S2. <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of 5.



**Figure S3.** <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of **6**.



Figure S4. <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of 6.



Figure S5. HSQC (150 MHz, CDCl<sub>3</sub>) spectrum of 6.

#### Table S1. NMR assignments 7a/7b mixture.



1		22 23 HN (+) 25
	<sup>1</sup> 16	

~3:1	ratio	7a/7b

Desition	<b>7a</b> <sup>a</sup>		<b>7b</b> <sup>a</sup>	
Position	$\delta_{\rm C}$	$\delta_{\rm H} \left( J \text{ in Hz} \right)$	$\delta_{\rm C}$	$\delta_{\rm H} \left( J \text{ in Hz} \right)$
1	36.4	3.88, m	36.7	3.88, m
2 a	40.0	2.09, m	40.0	2.09, m
b	-	1.24, m	-	1.24, m
3	34.5	1.24, m	34.4	1.24, m
4	44.67	2.20, m	44.72	2.20, m
5 a	28.0	2.13, m	28.0	2.13, m
b	-	1.04, m	-	1.04, m
ба	32.08	2.24, m	31.99	2.24, m
b	-	1.35, m	-	1.35, m
7	30.1	3.16, m	30.6	3.32, m
8	122.0	-	130.3	-
9	147.9	-	136.9	-
10	138.8	-	149.2	-
11	125.7	-	116.7	-
12	134.6	-	135.6	-
13	136.2	-	135.2	-
14	130.7	4.92, d (9.4)	130.5	
15	128.7	-	128.9	-
16	25.4	1.64, s	25.4	1.65, s
17	17.6	1.74, s	17.6	1.74, s
18	19.73	1.02, d (6.0)	19.77	1.02, d (6.0)
19	22.2	1.36, d (6.6)	23.8	1.41, d (6.6)
20	13.6	2.33, s	12.3	2.24, s
21	161.7	-	161.1	-
C21-Oxazole appendage (AA derived)	-	-	-	-
22	26.49	4.26, s	26.40	4.26, s
23	130.2	-	130.2	-
24	-	8.57 <sup>b</sup> , br	-	8.57 <sup>b</sup> , br
25	134.5	8.50 <sup>b</sup> , br s	134.5	8.50 <sup>b</sup> , br s
26	-	7.82 <sup>b</sup> , br	-	7.82 <sup>b</sup> , br
27	117.3	7.01, br s	117.5	7.01, br s

<sup>a</sup> CDCl3, 600 MHz (<sup>13</sup>C: 150 MHz); assigned by HSQC, HMBC & COSY. <sup>b</sup> interchangeable assignments. Note: The NMR data was acquired on material purified by HPLC (MeOH:H2O:HCO2H) and thus the imidazole moiety was protonated. The chemical shifts are sensitive to changes in pH.



Figure S6. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of **7a/7b** mixture.



Figure S7. <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of **7a/7b** mixture.



Figure S8. HSQC spectrum (600 MHz, CDCl<sub>3</sub>) of 7a/7b mixture.





Figure S10. Analytical UPLC Chromatogram of 7a/7b. (a) UV trace 255 nm; (b) ELSD trace; (c) Base peak mass chromatogram; (d) Selected ion monitoring m/z 390 [M + H]; (e) Average mass spectrum (5.15–5.45 min).



C:\Xcalibur\...\RKMM-TBSP-14SEP2010-D5

9/14/2010 11:37:54 PM



Figure S11. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of 8.



Figure S12. <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of 8.



Figure S13. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of 10.



Figure S14. <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of 10.



Figure S15. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of 11.



**Figure S16.** <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of **11**.



Figure S17. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of 12.



Figure S18. <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of 12.



Figure S19. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of 14.



**Figure S20.** <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of **14**.



Figure S21. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of 15.



Figure S22. <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of 15.



Figure S23. <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) spectrum of 16.



**Figure S24.** <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) spectrum of **16**.











4E+07

## **Figure S27.** <sup>1</sup>H-NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) spectrum of **18**.





# **Figure S28.** <sup>13</sup>C-NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) spectrum of **18**.









Note: some impurities are present: residual solvent  $CH_3OD$  at  $\delta$  3.35 and  $H_2O$  at  $\delta$  4.85. Baseline impurities appear to be glycosylated analogue(s) of **19**. Further HPLC purification of **19** was unsuccessful, however following deprotection compound **20** was purified and characterized.

**Figure S30.** <sup>13</sup>C-NMR (600 MHz, CD<sub>3</sub>OD) spectrum of **19**.





## **Figure S31.** <sup>1</sup>H-NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) spectrum of **20**.





## **Figure S32.** <sup>13</sup>C-NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) spectrum of **20**.





Scheme S1. Syntheses of 2,3,4,6-tetra-*O*-benzoyl- $\beta$ -D-galactopyranosyl trichloro acetimidate (21). Reagents and conditions: (a) BzCl (7.0 equiv.), Pyr; (b) HBr (3.0 equiv.), MeOH (2.0 equiv.), AcOH, 0 °C  $\rightarrow$  r.t., 36% over two steps; (c) Ag<sub>2</sub>CO<sub>3</sub> (1.2 equiv.), acetone:H<sub>2</sub>O (19:1), 85%; (d) CCl<sub>3</sub>CN (10 equiv.), K<sub>2</sub>CO<sub>3</sub> (1.2 equiv.), DCM, r.t. 36%.

